<DOC>
	<DOCNO>NCT01173978</DOCNO>
	<brief_summary>The incretin effect patient type two diabetes reduce . The investigator previously show possible induce defect incretin effect healthy individual . The purpose study evaluate insulinotropic affect incretin hormone healthy individual deterioration glucose homeostasis .</brief_summary>
	<brief_title>Insulinotropic Effect GIP GLP-1 Before After Reduced Glucose Tolerance</brief_title>
	<detailed_description>The incretin effect patient type two diabetes reduce . The investigator previously show possible induce defect incretin effect healthy individual . The purpose study evaluate insulinotropic affect incretin hormone healthy individual deterioration glucose homeostasis . The evaluation do infuse GIP , GLP-1 saline hyperglycemic clamp .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Caucasians without type 2 diabetes mellitus Normal OGTT ( 75 g glucose ) accord WHO 's criterion BMI 2030 Hemoglobin &gt; 8.0 mmol/l Informed consent Liver disease ( ALAT &gt; 2 x normal level ) Nephropathy ( screatinin &gt; 130 ÂµM albuminuria ) Relatives ( parents/siblings ) T2DM Medical treatment witch stop 12 hour</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Incretin hormone</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Insulin/c-peptide</keyword>
	<keyword>Plasma glucose</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Deteriorated glucose homeostasis</keyword>
	<keyword>Inactivity</keyword>
</DOC>